Based on the key measurements obtained from Instadose Pharma's financial statements, Instadose Pharma Corp may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Instadose Pharma's Accounts Payable is projected to increase significantly based on the last few years of reporting. The current year's Total Liabilities is expected to grow to about 196 K, whereas Net Tangible Assets are projected to grow to (138.8 K). Key indicators impacting Instadose Pharma's financial strength include:
The financial analysis of Instadose Pharma is a critical element in measuring its lifeblood. Investors should not minimize Instadose Pharma's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(395,030)
Instadose
Select Account or Indicator
Working Capital
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Average Payables
Pb Ratio
Roic
Net Income Per Share
Pocfratio
Pfcf Ratio
Net Current Asset Value
Income Quality
Roe
Tangible Asset Value
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Earnings Yield
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
Change To Netincome
Change To Liabilities
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Other Stockholder Equity
Total Liab
Net Invested Capital
Short Long Term Debt
Net Working Capital
Other Current Liab
Capital Stock
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Ebit
Total Operating Expenses
Income Before Tax
Net Income Applicable To Common Shares
Probability Of Bankruptcy
Understanding current and past Instadose Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Instadose Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Instadose Pharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Instadose Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Instadose Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Instadose Pharma's management manipulating its earnings.
Instadose Pharma Stock Summary
Instadose Pharma competes with Emergent Biosolutions, Collegium Pharmaceutical, Intracellular, and Durect. Instadose Pharma Corp. engages in growing, cultivation, processing, and global distribution of medical-grade cannabinoid oil. The company was founded in 2017 and is based in Burlington, Canada. Instadose Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Instadose Pharma's current stock value. Our valuation model uses many indicators to compare Instadose Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Instadose Pharma competition to find correlations between indicators driving Instadose Pharma's intrinsic value. More Info.
Instadose Pharma Corp is rated below average in return on asset category among its peers. It also is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Instadose Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Instadose Pharma Corp Systematic Risk
Instadose Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Instadose Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Instadose Pharma Corp correlated with the market. If Beta is less than 0 Instadose Pharma generally moves in the opposite direction as compared to the market. If Instadose Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Instadose Pharma Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Instadose Pharma is generally in the same direction as the market. If Beta > 1 Instadose Pharma moves generally in the same direction as, but more than the movement of the benchmark.
About Instadose Pharma Financials
What exactly are Instadose Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Instadose Pharma's income statement, its balance sheet, and the statement of cash flows. Potential Instadose Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Instadose Pharma investors may use each financial statement separately, they are all related. The changes in Instadose Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Instadose Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Today, most investors in Instadose Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Instadose Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Instadose Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(1.85)
At present, Instadose Pharma's Price Earnings To Growth Ratio is projected to drop slightly based on the last few years of reporting.
Complementary Tools for Instadose Stock analysis
When running Instadose Pharma's price analysis, check to measure Instadose Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Instadose Pharma is operating at the current time. Most of Instadose Pharma's value examination focuses on studying past and present price action to predict the probability of Instadose Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Instadose Pharma's price. Additionally, you may evaluate how the addition of Instadose Pharma to your portfolios can decrease your overall portfolio volatility.